MCID: ERY066
MIFTS: 30

Erythema Multiforme Major

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Erythema Multiforme Major

MalaCards integrated aliases for Erythema Multiforme Major:

Name: Erythema Multiforme Major 58 6 71
Erythema Exsudativum Multiforme Majus 58
Erythema Multiforme Majus 58
Stevens-Johnson Syndrome 71

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

Orphanet 58 ORPHA502499
UMLS 71 C0038325 C3241919

Summaries for Erythema Multiforme Major

MalaCards based summary : Erythema Multiforme Major, also known as erythema exsudativum multiforme majus, is related to erythema multiforme and severe cutaneous adverse reaction. An important gene associated with Erythema Multiforme Major is HLA-B (Major Histocompatibility Complex, Class I, B). The drugs Gabapentin and Phenytoin have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes.

Related Diseases for Erythema Multiforme Major

Diseases related to Erythema Multiforme Major via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 44, show less)
# Related Disease Score Top Affiliating Genes
1 erythema multiforme 11.8
2 severe cutaneous adverse reaction 10.5
3 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.5
4 exanthem 10.4
5 herpes simplex 10.3
6 stevens-johnson syndrome/toxic epidermal necrolysis 10.3
7 vascular disease 10.2
8 neutropenia 10.1
9 skin disease 10.1
10 bullous pemphigoid 10.1
11 pemphigus 10.1
12 autoimmune disease 10.0
13 major affective disorder 1 10.0
14 renal cell carcinoma, nonpapillary 10.0
15 immune deficiency disease 10.0
16 yemenite deaf-blind hypopigmentation syndrome 10.0
17 meningioma, radiation-induced 10.0
18 meningioma, familial 10.0
19 chlamydia pneumonia 10.0
20 pemphigus gestationis 10.0
21 disseminated intravascular coagulation 10.0
22 chlamydia 10.0
23 spinal meningioma 10.0
24 cicatricial pemphigoid 10.0
25 allergic hypersensitivity disease 10.0
26 quadriplegia 10.0
27 pemphigoid gestationis 10.0
28 thrombocytopenia 10.0
29 focal epilepsy 10.0
30 systemic scleroderma 10.0
31 secretory meningioma 10.0
32 lymphoplasmacyte-rich meningioma 10.0
33 pneumonia 10.0
34 conjunctivitis 10.0
35 acquired immunodeficiency syndrome 10.0
36 epilepsy with generalized tonic-clonic seizures 10.0
37 impetigo 10.0
38 herpes zoster 10.0
39 crohn's disease 10.0
40 alopecia areata 10.0
41 alopecia 10.0
42 neisseria meningitidis infection 10.0
43 bullous impetigo 10.0
44 acute liver failure 10.0

Graphical network of the top 20 diseases related to Erythema Multiforme Major:



Diseases related to Erythema Multiforme Major

Symptoms & Phenotypes for Erythema Multiforme Major

Drugs & Therapeutics for Erythema Multiforme Major

Drugs for Erythema Multiforme Major (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 126, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
3
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
4
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
7 Molgramostim Investigational Phase 4 99283-10-0
8 Pharmaceutical Solutions Phase 4
9 Ophthalmic Solutions Phase 4
10 Psychotropic Drugs Phase 4
11 Anticonvulsants Phase 4
12 Analgesics, Opioid Phase 4
13 Analgesics, Non-Narcotic Phase 4
14 Analgesics Phase 4
15 Excitatory Amino Acid Antagonists Phase 4
16 Anti-Anxiety Agents Phase 4
17 Hypolipidemic Agents Phase 4
18 Lipid Regulating Agents Phase 4
19 Antimetabolites Phase 4
20 Sodium Channel Blockers Phase 4
21 Diuretics, Potassium Sparing Phase 4
22 Anti-Arrhythmia Agents Phase 4
23 Neurotransmitter Agents Phase 4
24 Adrenergic Agents Phase 4
25 Adrenergic Antagonists Phase 4
26 Sympatholytics Phase 4
27 Adrenergic beta-Antagonists Phase 4
28
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
29
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
30
Lesinurad Approved, Investigational Phase 3 878672-00-5 53465279
31
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
32
Etravirine Approved Phase 3 269055-15-4 193962
33
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
34
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
35
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
36
tannic acid Approved Phase 2, Phase 3 1401-55-4
37 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
38
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
39
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
40
Azithromycin Approved Phase 2, Phase 3 83905-01-5 447043 55185
41
Lopinavir Approved Phase 2, Phase 3 192725-17-0 92727
42
Hydrocortisone Approved, Vet_approved Phase 2, Phase 3 50-23-7 5754
43
Hydrocortisone acetate Approved, Vet_approved Phase 2, Phase 3 50-03-3
44
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
45
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
48
Maraviroc Approved, Investigational Phase 2, Phase 3 376348-65-1 3002977
49
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
50
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
51
Etanercept Approved, Investigational Phase 3 185243-69-0
52
Coal tar Approved Phase 3 8007-45-2
53
Lamotrigine Approved, Investigational Phase 2, Phase 3 84057-84-1 3878
54
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
55 Hypoglycemic Agents Phase 3
56 Reverse Transcriptase Inhibitors Phase 3
57 Anti-Bacterial Agents Phase 2, Phase 3
58 Methylprednisolone Acetate Phase 2, Phase 3
59 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
60 Antiviral Agents Phase 2, Phase 3
61 Anti-Retroviral Agents Phase 2, Phase 3
62 Anti-HIV Agents Phase 2, Phase 3
63
protease inhibitors Phase 2, Phase 3
64 Hydrocortisone 17-butyrate 21-propionate Phase 2, Phase 3
65 Antiparasitic Agents Phase 2, Phase 3
66 Antiprotozoal Agents Phase 2, Phase 3
67 HIV Protease Inhibitors Phase 2, Phase 3
68 Hydrocortisone hemisuccinate Phase 2, Phase 3
69 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
70 Antimalarials Phase 2, Phase 3
71 Immunologic Factors Phase 3
72 Anti-Infective Agents Phase 3
73 Cyclosporins Phase 3
74 Antifungal Agents Phase 3
75 Immunosuppressive Agents Phase 3
76 Dermatologic Agents Phase 3
77 Calcineurin Inhibitors Phase 3
78 Antirheumatic Agents Phase 3
79 Gastrointestinal Agents Phase 3
80 Anti-Inflammatory Agents Phase 3
81 Anti-Inflammatory Agents, Non-Steroidal Phase 3
82 Antipsychotic Agents Phase 2, Phase 3
83 Calcium, Dietary Phase 2, Phase 3
84 calcium channel blockers Phase 2, Phase 3
85
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271
86
Amoxicillin Approved, Vet_approved Phase 1, Phase 2 26787-78-0 33613
87 Fibrin Tissue Adhesive Phase 1
88 Hemostatics Phase 1
89 Coagulants Phase 1
90 Anesthetics Phase 1
91 Anesthetics, Local Phase 1
92
Allopurinol Approved 315-30-0 2094
93
Isotretinoin Approved 4759-48-2 5282379 5538
94
Metformin Approved 657-24-9 14219 4091
95
Glyburide Approved 10238-21-8 3488
96
Carbamazepine Approved, Investigational 298-46-4 2554
97
Eslicarbazepine acetate Approved 75970-99-9, 236395-14-5 123618
98
Formaldehyde Approved, Vet_approved 50-00-0 712
99
Paroxetine Approved, Investigational 61869-08-7 43815
100
Fluoxetine Approved, Vet_approved 54910-89-3 3386
101
Sertraline Approved 79617-96-2 68617
102
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
103
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved 83-88-5 493570
104 Liver Extracts
105 Sitagliptin Phosphate
106 Incretins
107 Dipeptidyl-Peptidase IV Inhibitors
108 Antineoplastic Agents, Hormonal
109 Autoantibodies
110 Immunoglobulin A
111 Trace Elements
112 Micronutrients
113 Vitamins
114 Vitamin B Complex
115 Nutrients
116 Folate
117 Photosensitizing Agents
118 Vitamin B9
119 Vitamin B2
120 Dextrans
121 Antibodies
122 Immunoglobulins, Intravenous
123 Rho(D) Immune Globulin
124 gamma-Globulins
125 Immunoglobulins
126 Venlafaxine Hydrochloride

Interventional clinical trials:

(showing 56, show less)
# Name Status NCT ID Phase Drugs
1 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
2 A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Completed NCT01915082 Phase 4 Azithromycin;Ora-Plus
3 Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin on Post-operative Opioid Use and Patient Satisfaction Completed NCT01977937 Phase 4 Gabapentin 250mg/5mL NDC:59762-5025-01;Simple Syrup
4 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
5 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
6 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
7 Transdermal Lidocaine Patch for Post-Cesarean Pain Control for Women With Obesity: a Single-blind Randomized Controlled Trial Active, not recruiting NCT03810235 Phase 4 Transdermal Lidocaine Patch;Transdermal Hydrocolloid Placebo Patch
8 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
9 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
10 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
11 Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction Completed NCT01237600 Phase 2, Phase 3
12 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
13 A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor Completed NCT01508702 Phase 3 lesinurad;Placebo
14 A Phase III, Double Blind, Mulit-centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125. Completed NCT00792324 Phase 3 Etravirine;Efavirenz
15 Randomised Evaluation of COVID-19 Therapy Recruiting NCT04381936 Phase 2, Phase 3 Lopinavir-Ritonavir;Corticosteroid;Hydroxychloroquine;Azithromycin;Tocilizumab
16 Maraviroc to Augment Rehabilitation Outcomes After Stroke Recruiting NCT03172026 Phase 2, Phase 3 Maraviroc 300 mg;Placebo 300 mg
17 NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 Harmonized supportive care;Cyclosporine 5 mg/kg bid days 0-14;Etanercept 50 mg sc day 0 and day 3
18 Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study Terminated NCT00295776 Phase 2, Phase 3 Lamictal in the treatment of Post-Herpetic Neuralgia
19 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
20 Evaluation the Effect of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Epithelium Healing (Phase I and II Clinical Trial) Completed NCT02746848 Phase 1, Phase 2
21 Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-Centre Randomized Double Blind Controlled Trial in Pakistan Completed NCT00130013 Phase 1, Phase 2 Oral Amoxicillin
22 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
23 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
24 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
25 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
26 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
27 Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of Ocular Surface Reconstruction Completed NCT00344201 Phase 1
28 Topical Infliximab for the Treatment of Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
29 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Not yet recruiting NCT03878771 Phase 1 Dermovate cream in Orabase
30 Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction and Correlation With Disease Severity. Unknown status NCT03166241
31 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
32 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
33 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Unknown status NCT02795143 Isotretinoin
34 The Use of Pentacam in Assessment of Corneal Changes After Pterygium Excision Unknown status NCT03304366
35 The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation Unknown status NCT00696982 sitagliptin;glibenclamide
36 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
37 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
38 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions (SCAR) Completed NCT01276314 anti- TNF-a;Prednisolone
39 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
40 Evaluation of Immune Responses to Different Antigens in Non Infectious Ocular Inflammatory Diseases Completed NCT00357071
41 Safety and Effectiveness of a Laboratory Intervention to Effectively NOT Treat Asymptomatic Bacteriuria (SALIENT-A) Completed NCT03445312
42 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
43 Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients Recruiting NCT04252651
44 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
45 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Recruiting NCT02574988
46 The Effects of Autologous Simple Limbal Epithelial Transplantation. Recruiting NCT04021875
47 The Effects of Allogeneic Simple Limbal Epithelial Transplantation Recruiting NCT04021134
48 HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions: a Multicenter Clinical Study Recruiting NCT03184597
49 An Exploratory Case-Control Study of Genetic and Clinical Factors for Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate Recruiting NCT02520557
50 Corneal Collagen Crosslinking to Increase the Resistance of the Graft Used as a Support for the Boston Keratoprosthesis Type I Against Corneal Melting Recruiting NCT03041883
51 An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients Available NCT02149732
52 A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT03585946 Site specific standard of care comparison
53 Hypo-pigmented Skin Lesions in Children : Dermoscopic Evaluation Not yet recruiting NCT04089475
54 Heidelberg Retina Tomograph (HRT) in Vivo Confocal Microscopy to Evaluate the Ocular Surface Disorders of Healthy and Diseased Individuals Not yet recruiting NCT04025801
55 Histologic Evaluation Comparing Power Settings in Radiofrequency Ablation on Eyelash Follicles Not yet recruiting NCT03947723
56 Effectiveness of Basic Body Awareness Therapy in Survivors of Covid-19 and Health Workers Regarding Post-traumatic Stress Disorders Not yet recruiting NCT04396314

Search NIH Clinical Center for Erythema Multiforme Major

Genetic Tests for Erythema Multiforme Major

Anatomical Context for Erythema Multiforme Major

MalaCards organs/tissues related to Erythema Multiforme Major:

40
Skin, Eye, Testes, T Cells, Liver, Lung, Salivary Gland

Publications for Erythema Multiforme Major

Articles related to Erythema Multiforme Major:

(showing 3552, show less)
# Title Authors PMID Year
1
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. 6 61
29392710 2018
2
Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. 6 61
24597466 2014
3
HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. 61 6
23588310 2013
4
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. 6 61
23232549 2013
5
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. 61 6
21428768 2011
6
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. 61 6
16538176 2006
7
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. 6 61
15743917 2005
8
Medical genetics: a marker for Stevens-Johnson syndrome. 61 6
15057820 2004
9
The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. 6 61
8006430 1994
10
Altered levels of complement components associated with non-immediate drug hypersensitivity reactions. 61
31795786 2020
11
Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
32200005 2020
12
Highlights from the 2nd Biennial Stevens Johnson syndrome symposium 2019: SJS/TEN from Science to Translation. 61
31785388 2020
13
Alteplase treatment for massive lung atelectasis in a child with severe bronchiolitis obliterans complicating Stevens-Johnson syndrome. 61
32324952 2020
14
Expression of prostaglandin E2 receptor 3 in the eyelid epidermis of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
31000507 2020
15
Ectopic sebaceous glands of Gibsan in eyelid margin- A novel manifestation in Stevens Johnson Syndrome & proposed nomenclature based on an observational case series. 61
32194257 2020
16
Treatment for oral lesions in pediatric patients with Stevens-Johnson's syndrome: A case report and literature review. 61
31923328 2020
17
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children With Non-Hodgkin Lymphoma. 61
32576784 2020
18
Clinical clues predictive of Stevens-Johnson syndrome as the cause of chronic cicatrising conjunctivitis. 61
31630093 2020
19
Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. 61
32151629 2020
20
Differences in treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis at burn centers and non-burn centers. 61
32498082 2020
21
Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immune cell activation. 61
32561372 2020
22
Successful use of rifampin in a patient with Stevens-Johnson syndrome to rifabutin. 61
32169513 2020
23
Stevens-Johnson syndrome triggered by Levetiracetam-Caution for use with Carbamazepine. 61
32540638 2020
24
Stevens-Johnson Syndrome Secondary to Doxycycline Treatment in a Teenage Boy. 61
32574716 2020
25
[Advances in understanding of the pathophysiology of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)]. 61
32253008 2020
26
Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. 61
32052409 2020
27
Long-term Progression of Ocular Surface Disease in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 61
32028281 2020
28
A pediatric case of Stevens-Johnson syndrome/toxic epidermal necrolysis with rapid response to intravenous cyclosporine. 61
32509946 2020
29
Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China. 61
31898979 2020
30
Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis - diagnosis and treatment. 61
32469468 2020
31
An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. 61
32510242 2020
32
Association of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. 61
31896765 2020
33
Clinical trial to evaluate the therapeutic benefits of limbal-supported contact lens wear for ocular sequelae due to Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
32513522 2020
34
Reply to: "The age of procalcitonin: Potential pitfalls in critically ill patients with SJS/TEN. A comment on 'Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients'". 61
32092373 2020
35
The age of procalcitonin: potential pitfalls in critically ill patients with SJS/TEN. A comment on "Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients". 61
32092376 2020
36
The Association Between Concurrence of Infection and the Onset of Severe Eruption or Liver Injury in Patients Using Antipyretic Analgesics: A Matched, Nested Case-Control Study. 61
32521061 2020
37
Burn center admissions of patients with autoimmune rheumatic diseases: clinical characteristics and outcomes. 61
32507914 2020
38
General characteristics, economic burden, causative drugs and medical errors associated with medical damage litigation involving severe cutaneous adverse drug reactions in China. 61
32516456 2020
39
Traditional and advanced therapeutic modalities for wounds in the paediatric population: an evidence-based review. 61
32530778 2020
40
Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption. 61
32002848 2020
41
Mycoplasma Pneumoniae Induced Rash and Mucositis (MIRM): A Longitudinal Perspective and Proposed Management Criteria. 61
32574770 2020
42
Ventilatory support in Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. 61
32412819 2020
43
RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31954192 2020
44
Upper airway involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31591001 2020
45
The effects of systemic cyclosporine in acute Stevens-Johnson syndrome/toxic epidermal necrolysis on ocular disease. 61
32445836 2020
46
Erythema Multiforme Versus Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Subtle Difference in Presentation, Major Difference in Management. 61
32373930 2020
47
Two False Negative Test Results in a Symptomatic Patient with a Confirmed Case of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Suspected Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). 61
32455090 2020
48
Treatment of Oculoplastic and Ocular Surface Disease in Eyes Implanted with a Type I Boston Keratoprosthesis in Southern China: A Retrospective Study. 61
32436025 2020
49
Toxic epidermal necrolysis syndrome induced by tigecycline: a case report. 61
32400243 2020
50
Genetic variants associated with T cell-mediated cutaneous adverse drug reactions: A PRISMA-compliant systematic review-An EAACI position paper. 61
31899808 2020
51
Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. 61
31594365 2020
52
Genetic association of co-trimoxazole-induced severe cutaneous adverse reactions is phenotype-specific: HLA class I genotypes and haplotypes. 61
32452529 2020
53
Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children. 61
32272329 2020
54
CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events. 61
32454097 2020
55
Direct Injection of 5-Fluorouracil Improves Outcomes in Cicatrizing Conjunctival Disorders Secondary to Systemic Disease. 61
32427724 2020
56
Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report. 61
31567395 2020
57
Assessment of drug causality in Stevens-Johnson syndrome/toxic epidermal necrolysis: Concordance between lymphocyte transformation test and ALDEN. 61
31557316 2020
58
Use of Etanercept in a Series of Pediatric Patients With Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Spectrum Disease. 61
32347889 2020
59
Recurrent preseptal cellulitis in Boston keratoprosthesis type II implantation for ocular Stevens-Johnson syndrome. 61
31712017 2020
60
Readmission Risk Factors and Complications in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 61
32399363 2020
61
Therapeutic Effects of Mesenchymal Stem Cells on a Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Model. 61
32301297 2020
62
Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. 61
32154748 2020
63
Long-term sequelae from Stevens-Johnson syndrome / toxic epidermal necrolysis in a large retrospective cohort. 61
32289398 2020
64
Rash and Mucositis Associated With Mycoplasma pneumoniae and Chlamydophila pneumoniae: A Recurrence of MIRM? 61
32275058 2020
65
Comparison of Signal Detection Algorithms Based on Frequency Statistical Model for Drug-Drug Interaction Using Spontaneous Reporting Systems. 61
32356247 2020
66
SJS/TEN 2019: From science to translation. 61
32192826 2020
67
Preparation of placental tissue transplants and their application in skin wound healing and chosen skin bullous diseases - Stevens-Johnson syndrome and toxic epidermal necrolysis treatment. 61
31943788 2020
68
Individual- and hospital-level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012-2016. 61
31260078 2020
69
Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review. 61
31651559 2020
70
Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review. 61
32289395 2020
71
Application of a simple point-of-care test to reduce UK healthcare costs and adverse events in outpatient acute respiratory infections. 61
32259465 2020
72
Stevens Johnson Syndrome in a Patient with Giant Cell Arteritis During Short Term Tocilizumab Therapy. 61
32411563 2020
73
Stevens-Johnson syndrome/toxic epidermal necrolysis: a chronic condition? 61
31853947 2020
74
Early surgical correction of microstomia following Stevens-Johnson syndrome. 61
32380813 2020
75
Comparison of the ocular microbiome between chronic Stevens-Johnson syndrome patients and healthy subjects. 61
32152391 2020
76
Response: "Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review". 61
31712172 2020
77
Generalized Bullous Mucocutaneous Eruption Mimicking Stevens-Johnson Syndrome in the Setting of Immune Checkpoint Inhibition: A Multicenter Case Series. 61
32199891 2020
78
Reply to: "Response: Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review". 61
31712175 2020
79
Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003-16: a four-source capture-recapture estimate. 61
31396952 2020
80
Hypersensitivity reactions to proton-pump inhibitors: Clinical presentation, diagnosis, and management. 61
32122452 2020
81
Effect of phenytoin on retinal ganglion cells in acute isolated optic neuritis. 61
32212009 2020
82
Allogeneic Limbal Epithelial Transplantation Modified With Solid Platelet-Rich Plasma for Bilateral Limbal Stem Cell Deficiency. 61
32243415 2020
83
Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication. 61
31912576 2020
84
Updating the Burn Center Referral Criteria: Results from the 2018 eDelphi Consensus Study. 61
32123911 2020
85
Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy. 61
31848905 2020
86
Erythema Multiforme Major in a Dog Treated with Intravenous Human Immunoglobulin and Immunosuppressive Therapy. 61
31961218 2020
87
Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications. 61
32045311 2020
88
Shaping specialist treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
31742662 2020
89
Stevens-Johnson Syndrome: A Perplexing Diagnosis. 61
32328385 2020
90
Fatal pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis: Three case reports. 61
32195938 2020
91
Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). 61
32415695 2020
92
Searching for the Culprit Drugs for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis from a Nationwide Claim Database in Korea. 61
31614216 2020
93
Stevens-Johnson syndrome and toxic epidermal necrolysis - retrospective review of cases in a high complexity hospital in Brazil. 61
31173347 2020
94
Predictors of 30-day readmission in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cross-sectional database study. 61
31542405 2020
95
Retrospective review of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution. 61
32058621 2020
96
A retrospective analysis of infections and antibiotic treatment in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
30095319 2020
97
Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. 61
30702955 2020
98
Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017. 61
31870573 2020
99
Long-term and multiple hospital readmissions after discharge for Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
32017033 2020
100
Respiratory complications of Stevens-Johnson syndrome (SJS): 3 cases of SJS-induced obstructive bronchiolitis. 61
32067932 2020
101
The Clinical and Financial Impact of a Pharmacist-Driven Penicillin Skin Testing Program on Antimicrobial Stewardship Practices. 61
31983768 2020
102
Pattern-Specific Loss of Desmoplakin I and II Immunoreactivity in Erythema Multiforme and its Variants: A Possible Aid in Histologic Diagnosis. 61
31599750 2020
103
Beta-lactam allergy in the paediatric population. 61
32042244 2020
104
Management of immune checkpoint inhibitor-related dermatologic adverse events. 61
31814310 2020
105
Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications. 61
32100936 2020
106
Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017. 61
31997613 2020
107
Thiotepa hyperpigmentation preceding epidermal necrosis: malignant intertrigo misdiagnosed as Stevens-Johnson syndrome-toxic epidermal necrolysis overlap. 61
32239890 2020
108
The interferon-γ-induced protein 10/CXCR3 axis is associated with human herpesvirus-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms. 61
32037509 2020
109
Long-term visual outcomes of the Boston type I keratoprosthesis in Canada. 61
32066560 2020
110
Stevens-Johnson syndrome/toxic epidermal necrolysis associated with ecstasy exposure. 61
32109316 2020
111
Stevens-Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn's Disease. 61
32351742 2020
112
Is there an association between Stevens-Johnson Syndrome and vaccination? A systematic review. 61
31713580 2020
113
Attenuation of Wnt/β-catenin signaling in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31929762 2020
114
A case of Kawasaki disease presenting with atypical cutaneous involvement and mimicking Stevens-Johnson syndrome. 61
32232207 2020
115
Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer. 61
32207346 2020
116
Toxic epidermal necrolysis after radiotherapy for pleomorphic liposarcoma. 61
32155033 2020
117
The life-threatening eruptions of immune checkpoint inhibitor therapy. 61
32197753 2020
118
IVIG and under Burn Unit Care Yield Favorable Outcomes in Pediatric Patients with Toxic Epidermal Necrolysis: A Case Report and Literature Review. 61
32082644 2020
119
Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of HLA-B*15:02 Genotyping as Standard-of-Care. 61
32457602 2020
120
Trends in mortality rates for Stevens-Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017. 61
31323695 2020
121
Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the national pharmacovigilance center in Nigeria: a database review from 2004 to 2017. 61
32110375 2020
122
Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics. 61
32180714 2020
123
Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. 61
31951804 2020
124
Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting. 61
31608511 2020
125
CD39+ regulatory T cells modulate the immune response to carbamazepine in HLA-B*15:02 carriers. 61
31784043 2020
126
Multidisciplinary care in Stevens-Johnson syndrome. 61
32523661 2020
127
Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome. 61
32148986 2020
128
Common and critical inflammatory dermatoses every pathologist should know. 61
31676787 2020
129
Comment on: "Microbial Keratitis in Stevens-Johnson Syndrome: A Prospective Study". 61
31658166 2020
130
Validation of a clinical assessment tool for cicatrising conjunctivitis. 61
31693934 2020
131
Dermatoscopy in life-threatening and severe acute rashes. 61
32197741 2020
132
Two cases of Vici syndrome presenting with corpus callosum agenesis, albinism, and severe developmental delay. 61
32558422 2020
133
Bronchiolitis obliterans as a long-term sequela of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. 61
30908698 2019
134
The psychological impact of Stevens-Johnson syndrome and toxic epidermal necrolysis on patients' lives: a Critically Appraised Topic. 61
31792924 2019
135
Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. 61
31912590 2019
136
Comment on 'Bronchiolitis obliterans as a long-term sequela of Stevens-Johnson syndrome and toxic epidermal necrolysis in children'. 61
31323139 2019
137
Ribociclib-Related Stevens-Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review. 61
31897340 2019
138
Mutant GNLY is linked to Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31642954 2019
139
Depletion of regulatory FoxP3+ T cells in the pathogenesis of Stevens-Johnson syndrome induced by mogamulizumab. 61
31334834 2019
140
Evaluating Dry Eye and Meibomian Gland Dysfunction With Meibography in Patients With Stevens-Johnson Syndrome. 61
31205158 2019
141
Timing of mucocutaneous symptoms and medication discontinuation in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. 61
31085266 2019
142
Toxic epidermal necrolysis associated with pembrolizumab. 61
31810421 2019
143
Contrast media and cutaneous reactions. Part 2: Delayed hypersensitivity reactions to iodinated contrast media. 61
31162717 2019
144
Long-Term Effect of a Treatment Protocol for Acute Ocular Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 61
31326519 2019
145
Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. 61
30782092 2019
146
[Cutaneous lichen planus following Stevens-Johnson syndrome: Wolf's isotopic response]. 61
31627928 2019
147
Stevens-Johnson syndrome/toxic epidermal necrolysis: treatment with low-dose corticosteroids, vitamin C and thiamine. 61
31678920 2019
148
Carbonic anhydrase inhibitor-induced Stevens-Johnson syndrome/toxic epidermal necrolysis leads to extensive cutaneous involvement. 61
31128378 2019
149
Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor. 61
31342541 2019
150
Case of fertility treatment-induced Stevens-Johnson syndrome with a severe ocular complication. 61
31489686 2019
151
Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study. 61
31166019 2019
152
Stevens Johnson syndrome and toxic epidermal necrolysis - an Australian analysis of treatment outcomes and mortality. 61
30632424 2019
153
Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
31466921 2019
154
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Carbonic Anhydrase Inhibitors: Epidemiology, Genetics, and Insights into Mechanisms. 61
31706497 2019
155
Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. 61
31066027 2019
156
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. 61
31387950 2019
157
Ocular Side Effects of Systemic Drugs Used in Dermatology. 61
31896837 2019
158
Two pediatric cases of influenza B-induced rash and mucositis: Stevens-Johnson syndrome or expansion of the Mycoplasma pneumoniae-induced rash with mucositis (MIRM) spectrum? 61
31576583 2019
159
Nursing problems in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome in a Dutch burn centre: A 30-year retrospective study. 61
31387802 2019
160
Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review. 61
31436331 2019
161
Galectin-7 as a potential biomarker of Stevens-Johnson syndrome/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cells. 61
31100551 2019
162
Identification of HLA-A*02:06:01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing. 61
31700100 2019
163
Drug allergy. 61
31690398 2019
164
Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions. 61
31201937 2019
165
Drug-induced severe cutaneous adverse reactions: Determine the cause and prevention. 61
31400461 2019
166
HLA-B*58:01 Genotyping to Prevent Cases of DRESS and SJS/TEN in East Asians Treated with Allopurinol-A Canadian Missed Opportunity [Formula: see text]. 61
31378082 2019
167
Glaucoma Management in Patients With Aniridia and Boston Type 1 Keratoprosthesis. 61
31247168 2019
168
Contribution to oral and maxillary surgery and surgical technique of osteo-odontokeratoprosthesis in Japan. 61
31378404 2019
169
Ocular manifestations in patients with Stevens-Johnson syndrome in Malawi-review of the literature illustrated by clinical cases. 61
31352606 2019
170
Colonic Involvement of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Rare Cause of Gastrointestinal Bleeding. 61
31832469 2019
171
Contrast-induced generalized bullous fixed drug eruption resembling Stevens-Johnson syndrome. 61
31656435 2019
172
Authors' Reply to Cerejeira: "Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database". 61
31515698 2019
173
Comment on: "Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database". 61
31515699 2019
174
A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens-Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016. 61
30908601 2019
175
[Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors]. 61
31650946 2019
176
Association of Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs in pediatric patients: Subgroup analysis based on a Japanese spontaneous database. 61
31231846 2019
177
Recommendations for Prevention of Drug Re-Exposure in Toxic Epidermal Necrolysis 61
31603634 2019
178
[Mycoplasma pneumoniae-associated mucositis in a 17-year-old girl]. 61
31617477 2019
179
Ophthalmic Manifestations of Mycoplasma-Induced Rash and Mucositis. 61
31246679 2019
180
The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity. 61
31618895 2019
181
Bullous fixed drug eruption: A potential diagnostic pitfall: a study of 18 cases. 61
31006486 2019
182
Effect of Scleral Lens Wear on Central Corneal Thickness and Intraocular Pressure in Patients With Ocular Surface Disease. 61
31652178 2019
183
A State-of-the-Art Review Highlighting Medical Overuse in Dermatology, 2017-2018: A Systematic Review. 61
31642872 2019
184
Diagnostic Utility of Human Leukocyte Antigen B*15:02 Screening in Severe Carbamazepine Hypersensitivity Syndrome. 61
31736555 2019
185
[Drug-induced toxic epidermal necrolysis with secondary aspergillus fumigatus infection: a case report]. 61
31624410 2019
186
Erythema multiforme major associated with Mycoplasma pneumoniae infection. 61
31659061 2019
187
Corneal higher-order aberrations in Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31325631 2019
188
Clinical Outcome of Autologous Cultivated Oral Mucosal Epithelial Transplantation in Ocular Surface Reconstruction. 61
31356413 2019
189
Long-term outcomes of donor eyes after conjunctival limbal autograft and allograft harvesting. 61
31564346 2019
190
Stevens-Johnson syndrome complicated by fatal hemophagocytic lymphohistiocytosis. 61
31649973 2019
191
Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. 61
30086678 2019
192
Predicting sepsis in Stevens-Johnson syndrome-toxic epidermal necrolysis: Should dermatologists be pro-procalcitonin? 61
31420075 2019
193
Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. 61
30809807 2019
194
Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. 61
30825193 2019
195
Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and HLA-B*58:01 Genotype. 61
31308200 2019
196
Histomorphological Changes in Lachrymal Glands of Patients With Chronic Stevens-Johnson Syndrome. 61
31232745 2019
197
Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review. 61
31150704 2019
198
Stevens-Johnson syndrome and acute vanishing bile duct syndrome after the use of amoxicillin and naproxen in a child. 61
31448655 2019
199
Unusual oral findings of the toxic epidermal necrolysis in an HIV-infected patient: a case report. 61
31562853 2019
200
Sulfonamide Hypersensitivity: Fact and Fiction. 61
31495421 2019
201
Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients. 61
31195022 2019
202
Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. 61
31254013 2019
203
Pediatric SJS/TEN Subdued by a Combination of Dexamethasone, Cyclosporine, and Etanercept. 61
31478770 2019
204
Severe Cutaneous Adverse Reactions to Antiepileptic Drugs: A Nationwide Registry-Based Study in Korea. 61
31332981 2019
205
[Acetaminophen induced Stevens-Johnson syndrome in a child]. 61
31530358 2019
206
Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma. 61
31198688 2019
207
Skin scores: a review of clinical scoring systems in dermatology. 61
31675412 2019
208
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. 61
31327687 2019
209
Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity. 61
31434673 2019
210
Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. 61
30918988 2019
211
Vulvovaginal Manifestations in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Prevention and Treatment. 61
31437544 2019
212
Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database. 61
31041733 2019
213
Identification of drug-specific public TCR driving severe cutaneous adverse reactions. 61
31395875 2019
214
A review and guide to drug-associated oral adverse effects-Oral mucosal and lichenoid reactions. Part 2. 61
31241804 2019
215
Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. 61
31020549 2019
216
Making a diagnosis in severe cutaneous drug hypersensitivity reactions. 61
31247634 2019
217
Drug hypersensitivity in HIV infection. 61
31145192 2019
218
Long-term effect of corneoscleral contact lenses on refractory ocular surface diseases. 61
30389416 2019
219
Dermatologic Urgencies and Emergencies: What Every Pathologist Should Know. 61
30785787 2019
220
Microbial Keratitis in Stevens-Johnson Syndrome: A Prospective Study. 61
30998617 2019
221
Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. 61
31616210 2019
222
Incomplete Stevens-Johnson Syndrome Caused by Sulfonamide Antimicrobial Exposure. 61
31404173 2019
223
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus. 61
29912772 2019
224
Altered retinoid metabolism gene expression in chronic Stevens-Johnson syndrome. 61
31023710 2019
225
Stevens-Johnson Syndrome and Treatment With Clopidogrel. 61
30119955 2019
226
A case of recurrent Stevens-Johnson syndrome caused by nivolumab therapy. 61
31290394 2019
227
Intravenous cyclosporine in treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis: A case series. 61
31070856 2019
228
Multistep Grading System for Evaluation of Chronic Ocular Sequelae in Patients With Stevens-Johnson Syndrome. 61
30731084 2019
229
Lip synechiae: A rare complication of azithromycin-associated Stevens-Johnson syndrome. 61
31798262 2019
230
How different is Stevens-Johnson syndrome/toxic epidermal necrolysis in children? 61
31259411 2019
231
Sutureless amniotic membrane transplantation with cyanoacrylate glue for acute Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
30872140 2019
232
Coxsackievirus B5-induced severe mucocutaneous reaction mimicking drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
31062724 2019
233
The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 61
31365024 2019
234
The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-Reply. 61
31365027 2019
235
Dark skin phototype is associated with more severe ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
30633324 2019
236
International and multidisciplinary scientific collaborations and networks are advancing knowledge about Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31259394 2019
237
Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature. 61
30659711 2019
238
Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States. 61
31158306 2019
239
Direct in situ labeling of target drugs with a fluorophore probe to improve MALDI-MS detection sensitivity in micro-liter plasma. 61
31346224 2019
240
Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
30613954 2019
241
British Association of Dermatologists' guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. 61
30829411 2019
242
Genetic testing for prevention of severe drug-induced skin rash. 61
31314143 2019
243
Recurrent erythema multiforme major in an 8-year-old patient with recurrence of herpetic gingivostomatitis and HLA-B*5801 haplotype: A causal or casual relationship? 61
31341940 2019
244
Erythema Multiforme: Recognition and Management. 61
31305041 2019
245
Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond. 61
31384575 2019
246
[Warning symptoms skin: cutaneous manifestation of drug allergy]. 61
31282839 2019
247
[Allergies to non-betalactam antibiotics: a challenge in practice]. 61
31282834 2019
248
Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. 61
30242287 2019
249
Mucosal Lichen Planus Mimicking Mucosal Lesions in Stevens-Johnson Syndrome after Nivolumab Therapy. 61
30938822 2019
250
A modified technique for bedside amniotic membrane application to the eyelid margins for Stevens-Johnson syndrome. 61
31109496 2019
251
Presumed Sulfonamide-Associated Uveitis With Stevens-Johnson Syndrome in a Quarter Horse Mare. 61
31133310 2019
252
Characteristics of meibomian gland dysfunction in patients with Stevens-Johnson syndrome. 61
31261544 2019
253
HLA-associated antiepileptic drug-induced cutaneous adverse reactions. 61
30895730 2019
254
Antiepileptic drug-induced severe cutaneous adverse reactions and HLA alleles: A report of five cases with lymphocyte activation test. 61
32055583 2019
255
Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevalence and patients' characteristics. 61
30395917 2019
256
Pancytopenia in a Patient with Stevens-Johnson Syndrome: A Case Report with Literature Review. 61
31355064 2019
257
Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series. 61
30430542 2019
258
Prosthetic Replacement of the Ocular Surface Ecosystem Treatment for Ocular Surface Disease in Pediatric Patients With Stevens-Johnson Syndrome. 61
30664843 2019
259
Interventions for erythema multiforme: a systematic review. 61
30680804 2019
260
Outpatient management and follow-up recommendations for adverse drug reactions: guidelines for posthospitalization care. 61
31233575 2019
261
Analysis of Cutaneous Adverse Drug Reactions Reported at the Regional ADR Monitoring Center. 61
31148872 2019
262
Drug-induced liver injury with skin reactions: Drugs and host risk factors, clinical phenotypes and prognosis. 61
30515930 2019
263
Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients. 61
30282109 2019
264
Intravenous immunoglobulin treatment: Where do dermatologists stand? 61
30756448 2019
265
Severe Cutaneous Adverse Reactions during Tapering of High-Dose Systemic Steroid Therapy for Autoimmune Diseases: Implications for Non-HIV Immune Reconstitution Inflammatory Syndrome. 61
31275132 2019
266
[Anti-laminin 332 mucous membrane pemphigoid with irreversible ocular and tracheobronchial involvement : Delayed diagnosis of a severe autoimmune bullous disease]. 61
30963224 2019
267
Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report. 61
31083216 2019
268
Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: Proportion and determinants of underreporting to pharmacovigilance. 61
30292922 2019
269
[Cutaneous Adverse Drug Reaction Caused by Antiepileptic Drug]. 61
30988229 2019
270
Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. 61
30840032 2019
271
Association of human antigen class I genes with cold medicine-related Stevens-Johnson syndrome with severe ocular complications in a Korean population. 61
30705045 2019
272
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. 61
30399387 2019
273
An Update on Adverse Cutaneous Drug Reactions in HIV/AIDS. 61
31700852 2019
274
Spontaneous Resolution of Cholesteatoma in a Patient on Long-Term Infliximab. 61
30632386 2019
275
Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database. 61
30689189 2019
276
Spontaneous cutaneous adverse drug reaction reports-An analysis of a 10-year dataset in Singapore. 61
30911397 2019
277
[Lamotrigine induced hypersensitivity syndrome in children: a case report]. 61
30996382 2019
278
Topical moxifloxacin-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. 61
31036782 2019
279
[A Case of Stevens-Johnson Syndrome Induced by Chemotherapy for Metastatic Colon Cancer]. 61
31164523 2019
280
Allopurinol-Induced Stevens-Johnson Syndrome. 61
30638600 2019
281
Corneal Limbal Stem Cell Deficiency in Children with Stevens-Johnson Syndrome. 61
30347185 2019
282
A Case of Stevens-Johnson Syndrome After Exposure to Valproic Acid. 61
30947405 2019
283
Novel complication of Flakka: Stevens-Johnson syndrome/Toxic epidermal necrolysis overlap. 61
30503281 2019
284
Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome. 61
30968035 2019
285
The rash that presents as target lesions. 61
30981295 2019
286
Ciprofloxacin-Induced Bullae of the Lower Extremity: A Case of a Fixed Drug Reaction. 61
31135195 2019
287
Making Rash Decisions in Epilepsy: Evaluating Hypersensitivity Reactions to Anti-seizure Medications. 61
30955419 2019
288
Phenotypes of Severe Cutaneous Adverse Reactions Caused by Nonsteroidal Anti-inflammatory Drugs. 61
30661313 2019
289
Severe Cutaneous Adverse Reactions in Korean Pediatric Patients: A Study From the Korea SCAR Registry. 61
30661316 2019
290
Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population. 61
30826555 2019
291
Scoring systems for allergies and asthma in clinical research and practice. 61
30563587 2019
292
Stevens-Johnson syndrome. 61
30406877 2019
293
Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer. 61
30612819 2019
294
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn's disease: Need for a multidisciplinary approach. 61
30541717 2019
295
Comprehensive assessment of T cell receptor β repertoire in Stevens-Johnson syndrome/toxic epidermal necrolysis patients using high-throughput sequencing. 61
30623817 2019
296
Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. 61
30298362 2019
297
Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis. 61
30129156 2019
298
Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea. 61
30666843 2019
299
Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data. 61
30254188 2019
300
Radiation-induced dermatitis after administration of mogamulizumab for adult T-cell leukaemia/lymphoma: a multi-institutional retrospective study. 61
30452692 2019
301
Ocular Surface Reconstruction Using Circumferentially-trephined Autologous Oral Mucosal Graft Transplantation in Limbal Stem Cell Deficiency. 61
30746908 2019
302
Spectrum of gastrointestinal involvement in Stevens - Johnson syndrome. 61
30788030 2019
303
Bronchiolitis Obliterans After Cefuroxime-Induced Stevens-Johnson Syndrome. 61
30737366 2019
304
Fluoxetine-induced Stevens-Johnson syndrome and liver injury. 61
30296343 2019
305
A Case Study of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis (SJS-TEN) Overlap in Mycoplasma pneumoniae-Associated Tracheobronchitis. 61
31275674 2019
306
Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens-Johnson syndrome. 61
29256167 2019
307
Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
30830062 2019
308
Defining Regional Differences in Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Tool to Improve Drug Safety? 61
30120778 2019
309
A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. 61
29859332 2019
310
Lacrimal passage irrigation in children with Stevens-Johnson syndrome or toxic epidermal necrolysis: a five-year retrospective study. 61
30658599 2019
311
Prognostication Using SCORTEN Severity of Illness Score in Patients With Stevens Johnson Syndrome and Toxic Epidermal Necrolysis. 61
30273718 2019
312
A Review of the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 61
30702535 2019
313
Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
30285308 2019
314
Stevens-Johnson syndrome-like reaction without mucosal lesions associated with cyclophosphamide. 61
30504533 2019
315
Ocular and Mucocutaneous Sequelae among Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Togo. 61
30838038 2019
316
Ciprofloxacin-induced Stevens-Johnson Syndrome with Grapefruit Juice Consumption: A Case Report. 61
30868040 2019
317
Gene expression analysis of conjunctival epithelium of patients with Stevens-Johnson syndrome in the chronic stage. 61
31276031 2019
318
Stevens-Johnson Syndrome complicated by obstructive uropathy, pneumothorax, and pneumomediastinum: a case report and literature review. 61
31205959 2019
319
Association of IKZF1 SNPs in cold medicine-related Stevens-Johnson syndrome in Thailand. 61
31768251 2019
320
Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of six cases. 61
31990471 2019
321
Complication during hospitalization of geronto-psychiatric patient for fatal Stevens-Johnson syndrome - a multidisciplinary approach. 61
31996000 2019
322
[Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy]. 61
31787645 2019
323
An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions. 61
31692425 2019
324
Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. 61
31696806 2019
325
Anesthesia Considerations in Modified Osteo-odonto-keratoprosthesis. 61
29983007 2019
326
Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007⁻2018. 61
30658389 2019
327
Outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in HIV-infected patients when using systemic steroids and/or intravenous immunoglobulins in Pietermaritzburg, South Africa. 61
31308970 2019
328
The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. 61
29569740 2019
329
Development of an electronic medical record-based algorithm to identify patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan. 61
31408480 2019
330
Association of HLA class I and II gene polymorphisms with acetaminophen-related Stevens-Johnson syndrome with severe ocular complications in Japanese individuals. 61
31666976 2019
331
[Recalcitrant cicatrizing conjunctivitis. Treatment of nine patients with rituximab]. 61
31487253 2019
332
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study. 61
30112729 2019
333
Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions. 61
31696807 2019
334
Adult-onset autoimmune-type enteropathy: potential relationship to an adverse drug reaction. 61
31875138 2019
335
Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients. 61
30726458 2019
336
Controversies in drug allergy: Testing for delayed reactions. 61
30573342 2019
337
Empyema Necessitans due to Interruption of Antituberculosis Treatment. 61
31275673 2019
338
A Computational Platform and Guide for Acceleration of Novel Medicines and Personalized Medicine. 61
30848462 2019
339
Treatment of oral manifestations of toxic epidermal necrolysis with low-level laser therapy in a pediatric patient. 61
30474865 2019
340
Ocular Surface Microbial Flora in Patients with Chronic Limbal Stem Cell Deficiency Undergoing Cultivated Oral Mucosal Epithelial Transplantation. 61
31114120 2019
341
Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs. 61
29800753 2019
342
Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea. 61
29466850 2019
343
Role of in vivo and in vitro Tests in the Diagnosis of Severe Cutaneous Adverse Reactions (SCAR) to Drug. 61
31696801 2019
344
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. 61
30509740 2019
345
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview. 61
30058498 2019
346
Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization. 61
30468876 2019
347
Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma. 61
30729055 2019
348
Stevens Johnson Syndrome with Vaginal Pain and Lesions as Initial Presentation. 61
30573724 2018
349
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report. 61
30301570 2018
350
Minimal clinically important differences for measures of treatment efficacy in Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
29890189 2018
351